DE69712731D1 - Verfahren zur überwachung der chemotherapie von hiv-positiven patienten basierend auf der phenotypischen medikamentempfindlichkeit vom hiv stamm des patienten - Google Patents

Verfahren zur überwachung der chemotherapie von hiv-positiven patienten basierend auf der phenotypischen medikamentempfindlichkeit vom hiv stamm des patienten

Info

Publication number
DE69712731D1
DE69712731D1 DE69712731T DE69712731T DE69712731D1 DE 69712731 D1 DE69712731 D1 DE 69712731D1 DE 69712731 T DE69712731 T DE 69712731T DE 69712731 T DE69712731 T DE 69712731T DE 69712731 D1 DE69712731 D1 DE 69712731D1
Authority
DE
Germany
Prior art keywords
hiv
chimeric
sensitivity
inhibitor
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69712731T
Other languages
English (en)
Other versions
DE69712731T2 (de
Inventor
Bethune Marie-Pierre De
Kurt Hertogs
Rudi Pauwels
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virco BVBA
Original Assignee
Virco BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virco BVBA filed Critical Virco BVBA
Publication of DE69712731D1 publication Critical patent/DE69712731D1/de
Application granted granted Critical
Publication of DE69712731T2 publication Critical patent/DE69712731T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE69712731T 1996-01-26 1997-01-24 Verfahren zur überwachung der chemotherapie von hiv-positiven patienten basierend auf der phenotypischen medikamentempfindlichkeit vom hiv stamm des patienten Expired - Lifetime DE69712731T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96200175 1996-01-26
PCT/IB1997/000071 WO1997027480A1 (en) 1996-01-26 1997-01-24 Method of managing the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains

Publications (2)

Publication Number Publication Date
DE69712731D1 true DE69712731D1 (de) 2002-06-27
DE69712731T2 DE69712731T2 (de) 2003-02-06

Family

ID=8223611

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69712731T Expired - Lifetime DE69712731T2 (de) 1996-01-26 1997-01-24 Verfahren zur überwachung der chemotherapie von hiv-positiven patienten basierend auf der phenotypischen medikamentempfindlichkeit vom hiv stamm des patienten

Country Status (21)

Country Link
US (3) US6221578B1 (de)
EP (1) EP0877937B1 (de)
KR (1) KR100495690B1 (de)
CN (2) CN1209875A (de)
AT (1) ATE217971T1 (de)
AU (1) AU717755B2 (de)
BG (1) BG102710A (de)
BR (1) BR9707204A (de)
CZ (1) CZ292899B6 (de)
DE (1) DE69712731T2 (de)
ES (1) ES2177922T3 (de)
HU (1) HU226203B1 (de)
IL (1) IL125442A (de)
IS (1) IS4799A (de)
NO (1) NO321329B1 (de)
NZ (1) NZ325912A (de)
PL (1) PL186473B1 (de)
SK (1) SK283878B6 (de)
TR (1) TR199801443T2 (de)
WO (1) WO1997027480A1 (de)
ZA (1) ZA97669B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2140929C (en) 1992-08-25 2006-09-12 Michael L. Vazquez Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US20030220276A1 (en) * 1995-05-16 2003-11-27 Opendra Narayan HIV vaccine and method of use
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US20070010471A1 (en) * 1997-05-02 2007-01-11 Opendra Narayan HIV DNA vaccine
CA2298102A1 (en) * 1997-07-30 1999-02-11 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
CN1204266C (zh) * 1998-05-26 2005-06-01 病毒科学公司 监控非核苷类逆转录酶抑制剂抗逆转录病毒治疗的途径与方法
ATE302287T1 (de) 1999-05-28 2005-09-15 Virco Nv Neue mutationsprofile der hiv-1 reverse transcriptase in verbindung mit phänotypischem medikamentresistenz
US6800437B1 (en) 1999-08-06 2004-10-05 Tibotec Bvba Method of monitoring a biological system by labeling with an apo metal binding protein
EP1109019A1 (de) * 1999-12-15 2001-06-20 BioStrands S.r.l. Verfahren zur Ermittlung der Empfindlichkeit von HIV-Varianten gegen Hemmstoffe der HIV-Protease
AU2001233513A1 (en) * 2000-02-04 2001-08-14 K.U. Leuven Research And Development Hiv-1 resistance assay
GB0009374D0 (en) * 2000-04-14 2000-05-31 Glaxo Group Ltd Phenotyping assay and reagents therefor
DE60135366D1 (de) * 2000-04-18 2008-09-25 Virco Bvba Methode zur bestimmung der resistenz gegen medikamente
US6800463B1 (en) 2000-04-20 2004-10-05 Virco Bvba Method for mutation detection in HIV-1 using pol sequencing
AU2001256318B8 (en) * 2000-04-20 2007-03-22 Virco Bvba Method for mutation detection in HIV using pol sequencing
US6582901B2 (en) 2000-04-26 2003-06-24 Bruce K. Patterson Cell specific anti-viral drug susceptibility test using tagged permissive target cells
US7058616B1 (en) 2000-06-08 2006-06-06 Virco Bvba Method and system for predicting resistance of a disease to a therapeutic agent using a neural network
CN1446265A (zh) * 2000-06-12 2003-10-01 病毒科学公司 检测抗反转录病毒治疗的方式与方法和在hiv/aids治疗中的指导治疗方案
US6582920B2 (en) * 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
JP2004512032A (ja) 2000-10-20 2004-04-22 ビルコ・ビーブイビーエイ 表現型薬物耐性と相互に関連付けられるｈｉｖ−１逆転写酵素中の新たな突然変異の特徴
US7292944B2 (en) 2000-10-20 2007-11-06 Virco Bvba Establishment of biological cut-off values for predicting resistance to therapy
US7306901B2 (en) 2001-08-08 2007-12-11 Tibotec Pharmaceuticals, Ltd. Methods and means for assessing HIV envelope inhibitor therapy
US6958211B2 (en) * 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
JP2005513420A (ja) 2001-11-08 2005-05-12 テイボテク・フアーマシユーチカルズ・リミテツド 治療薬をモニタリングするためのプロテアーゼアッセイ
ATE397669T1 (de) 2002-07-01 2008-06-15 Tibotec Pharm Ltd Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase
DE60327768D1 (de) 2002-07-01 2009-07-09 Tibotec Pharm Ltd Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
JP5213228B2 (ja) * 2004-03-02 2013-06-19 ビルコ・ビーブイビーエイ 臨床的カット−オフ値の推測
CN101365808B (zh) 2005-12-07 2012-04-25 泰博特克药品有限公司 用于评估hiv病毒适应度的方法、质粒载体和引物
EP2010680A2 (de) * 2006-04-14 2009-01-07 Tibotec Pharmaceuticals Ltd. Verfahren und mittel zur beurteilung von hiv-gag-/proteasehemmer-therapie
EP2162745A1 (de) 2007-05-25 2010-03-17 Tibotec Pharmaceuticals Neues mutationsprofil bei einer hiv1-gag-spaltstelle in korrelation mit phänotypischer arzneistoffresistenz
EP2342363B1 (de) * 2008-10-06 2015-06-10 Janssen Diagnostics BVBA Verfahren zur bestimmung von arzneistoffresistenz-mutationen in einem der nicht-strukturprotein-bereiche ns3 bis ns5b von hepatitis c-virus (hcv) für genotypen 1 bis 6
US20120064514A1 (en) * 2009-05-12 2012-03-15 Virco Bvba Hiv-1-c resistance monitoring
CN107085093B (zh) * 2017-03-24 2019-06-21 西藏诺迪康药业股份有限公司 重组人白细胞介素1受体拮抗剂滴眼液生物学活性的检测方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875396A (en) * 1973-11-12 1975-04-01 Illuminite Corp Illuminated clipboard
US4675147A (en) * 1983-04-06 1987-06-23 Westinghouse Electic Corp. Generating an integrated graphic display of the safety status of a complex process plant
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
IL94482A (en) 1989-05-25 2003-09-17 Univ Duke Transdominant repressor mutant of retroviral protein, dna encoding the protein and process for their preparation and use thereof
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
JPH05148202A (ja) * 1991-04-10 1993-06-15 Tsumura & Co 新規な化合物およびその医薬としての用途
WO1993023574A1 (en) 1992-05-14 1993-11-25 Kozal Michael J Polymerase chain reaction assays for monitoring antiviral therapy
US5733720A (en) 1992-06-18 1998-03-31 Washington University Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor
ES2113546T3 (es) 1992-07-06 1998-05-01 Harvard College Metodos y estuches de diagnostico para determinar la toxicidad de un compuesto utilizando promotores de estres bacterianos fusionados con genes reporteros.
US5344846A (en) 1992-12-30 1994-09-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells
US5591579A (en) 1993-12-21 1997-01-07 Washington University Indicator cell line for detecting RNA viruses and method therefor
US6063562A (en) * 1994-09-16 2000-05-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
WO1997012220A2 (en) 1995-09-15 1997-04-03 Samir Chachoua Method for the identification and therapeutic use of disease-associated organisms, elements and forces
US5885806A (en) * 1995-11-28 1999-03-23 The Johns Hopkins University School Of Medicine Methods to prepare conditionally replicating viral vectors
ES2175355T3 (es) 1996-01-29 2002-11-16 Virologic Inc Composiciones y metodos para determinar la susceptibilidad y la resistencia a farmacos antivirales y rastreo de farmacos antivirales.
US5837464A (en) 1996-01-29 1998-11-17 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US5945276A (en) 1996-04-10 1999-08-31 Signal Pharmaceuticals, Inc. Reporter cell line system for detecting cytomegalovirus and identifying modulators of viral gene expression
US5939253A (en) 1996-04-26 1999-08-17 Diagnostic Hybrids, Inc. Compositions and methods for detecting viral infection
DE69837118T2 (de) 1997-04-07 2007-12-27 Fisher Biolmage Aps Ein Verfahren zum Screenen von Substanzen hinsichtlich ihres Effekts auf cAMP Spiegel basierend auf intrazellulärer Translokation von PKA
WO1998046796A1 (en) 1997-04-11 1998-10-22 The Regents Of The University Of California A method of screening nucleotide sequences to identify disruptors or effectors of biological processes or pathways
WO1998059074A1 (en) 1997-06-23 1998-12-30 Emory University Human immunodeficiency viruses causing aids in a nonhuman primate
US5976813A (en) 1997-12-12 1999-11-02 Abbott Laboratories Continuous format high throughput screening

Also Published As

Publication number Publication date
SK283878B6 (sk) 2004-04-06
IS4799A (is) 1998-07-20
EP0877937B1 (de) 2002-05-22
PL186473B1 (pl) 2004-01-30
ZA97669B (en) 1998-06-25
US20020042679A1 (en) 2002-04-11
SK100298A3 (en) 1999-02-11
WO1997027480A1 (en) 1997-07-31
HUP9902618A2 (hu) 1999-12-28
ES2177922T3 (es) 2002-12-16
HU226203B1 (en) 2008-06-30
EP0877937A1 (de) 1998-11-18
KR19990082027A (ko) 1999-11-15
BG102710A (en) 1999-03-31
HUP9902618A3 (en) 2001-04-28
IL125442A0 (en) 1999-03-12
ATE217971T1 (de) 2002-06-15
PL328069A1 (en) 1999-01-04
CZ292899B6 (cs) 2003-12-17
US6528251B2 (en) 2003-03-04
NO321329B1 (no) 2006-04-24
TR199801443T2 (xx) 1998-10-21
NZ325912A (en) 1999-01-28
CZ233598A3 (cs) 1999-06-16
AU717755B2 (en) 2000-03-30
DE69712731T2 (de) 2003-02-06
KR100495690B1 (ko) 2005-11-08
BR9707204A (pt) 1999-12-28
CN1209875A (zh) 1999-03-03
NO983300L (no) 1998-09-25
US6221578B1 (en) 2001-04-24
AU1316897A (en) 1997-08-20
NO983300D0 (no) 1998-07-16
IL125442A (en) 2002-03-10
US20030152917A1 (en) 2003-08-14
CN1991365A (zh) 2007-07-04

Similar Documents

Publication Publication Date Title
DE69712731D1 (de) Verfahren zur überwachung der chemotherapie von hiv-positiven patienten basierend auf der phenotypischen medikamentempfindlichkeit vom hiv stamm des patienten
Konigsberg Migration models of prehistoric postmarital residence
Martin Nucleic acid chaperone properties of ORF1p from the non-LTR retrotransposon, LINE-1
Mysara et al. Reconciliation between operational taxonomic units and species boundaries
Shearer et al. Utilizing ethnic-specific differences in minor allele frequency to recategorize reported pathogenic deafness variants
Reeves et al. Too much of a good thing: mechanisms of gene action in Down syndrome
Moens et al. Chromosome number of a small protist: accurate determination
Bhardwaj et al. Differential expression of HERV-K (HML-2) proviruses in cells and virions of the teratocarcinoma cell line Tera-1
Aune et al. Epigenetic activation and silencing of the gene that encodes IFN-γ
Mostowy et al. The role of recombination for the coevolutionary dynamics of HIV and the immune response
Elsner et al. Absence of cGAS-mediated type I IFN responses in HIV-1–infected T cells
Chatterjee et al. Serial number tagging reveals a prominent sequence preference of retrotransposon integration
White et al. Transcriptional modulation of human endogenous retroviruses in primary CD4+ T cells following vorinostat treatment
Riou et al. Severe symptomatic primary human cytomegalovirus infection despite effective innate and adaptive immune responses
van den Ham et al. From the two-dimensional Th1 and Th2 phenotypes to high-dimensional models for gene regulation
Roy Chowdhury et al. NK-like CD8+ γδ T cells are expanded in persistent Mycobacterium tuberculosis infection
Badia et al. Zinc finger endonuclease targeting PSIP1 inhibits HIV-1 integration
Li et al. Different rates of DNA replication at early versus late S‐phase sections: Multiscale modeling of stochastic events related to DNA content/EdU (5‐ethynyl‐2′ deoxyuridine) incorporation distributions
Zhao et al. Detection of regional variation in selection intensity within protein-coding genes using DNA sequence polymorphism and divergence
DuBose et al. Dynamic features of chromosomal instability during culture of induced pluripotent stem cells
Berrocal et al. Unified bursting strategies in ectopic and endogenous even-skipped expression patterns
Power Assessing fish population responses to stress
Dawson et al. Electrochemical noise--some new developments in corrosion monitoring
Chen et al. Methods taught in dental schools for determining the posterior palatal seal region.
DE60018117D1 (de) Methodologie um pflanzen und andere organismen mit von der normalen probe abweichenden charakteristiken zu identifizieren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition